Search

Home > The Bio Report > Genentech Drug Offers Oral, at-Home Option for SMA Patients
Podcast: The Bio Report
Episode:

Genentech Drug Offers Oral, at-Home Option for SMA Patients
Category: Business
Duration: 00:25:49
Publish Date: 2020-08-13 13:31:10
Description: People with the rare and fatal genetic disease spinal muscular atrophy in recent years have seen the approval of an antisense therapy as well as a gene therapy. Genentech has now won U.S. Food and Drug Administration approval for Evrysdi, the first oral, at-home treatment for the condition. We spoke to Levi Garraway, chief medical officer and head of global product development at Genentech, about Evrysdi, how it works, and how it fits into the choices physicians and patients have when it comes to treating spinal muscular atrophy.
Total Play: 0

Some more Podcasts by Levine Media Group

600+ Episodes
The Bio Repo ..